Lead: Emergency Department–Initiated Buprenorphine for Opioid Use Disorder
No se pudo agregar al carrito
Add to Cart failed.
Error al Agregar a Lista de Deseos.
Error al eliminar de la lista de deseos.
Error al añadir a tu biblioteca
Error al seguir el podcast
Error al dejar de seguir el podcast
Lead: Emergency Department–Initiated Buprenorphine for Opioid Use Disorder
-
Narrado por:
-
De:
Emergency Department–Initiated Buprenorphine for Opioid Use Disorder
JAMA Network
This multicenter randomized study examined if 7-day extended-release injectable buprenorphine compared with sublingual buprenorphine to improve treatment engagement at 7 days. It included 1,994 adult patients presenting to the emergency department with untreated opioid use disorder and a Clinical Opiate Withdrawal Scale (COWS) score of 4 or higher. In treatment at 7 days, 40.5% were in the extended-release group and 38.5% were in the sublingual buprenorphine group, demonstrating no significant difference between groups. The study concluded that a 7-day extended-release injectable preparation of buprenorphine does not improve treatment engagement.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM